PE20110546A1 - Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk) y produccion de los mismos - Google Patents

Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk) y produccion de los mismos

Info

Publication number
PE20110546A1
PE20110546A1 PE2011000917A PE2011000917A PE20110546A1 PE 20110546 A1 PE20110546 A1 PE 20110546A1 PE 2011000917 A PE2011000917 A PE 2011000917A PE 2011000917 A PE2011000917 A PE 2011000917A PE 20110546 A1 PE20110546 A1 PE 20110546A1
Authority
PE
Peru
Prior art keywords
amino
cycline
cdk
inhibitors
dependent kinases
Prior art date
Application number
PE2011000917A
Other languages
English (en)
Inventor
Ulrich Lucking
Rolf Jautelat
Gerhard Siemeister
Julia Schulze
Philip Lienau
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of PE20110546A1 publication Critical patent/PE20110546A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE PIRIMIDINA DE FORMULA (I), DONDE X ES O O NH; R1 ES METILO, ETILO, PROPILO O ISOPROPILO; R2 Y R3 SONH, METILO O ETILO; R4 ES ALQUILO C1-C6 O UN ANILLO CICLOALQUILO C3-C7. SON COMPUESTOS PREFERIDOS: (RS)-S-CICLOPROPIL-S-(4-{[4-{[(1R,2R)-2-HIDROXI-1-METILPROPIL]OXI}-5-(TRIFLUOROMETIL)PIRIMIDIN-2-IL]AMINO}FENIL)SULFOXIMIDA, (RS)-S-(4-{[4-{[(R)-2-HIDROXI-1,2-DIMETILPROPIL]OXI}-5-(TRIFLUOROMETIL)PIRIMIDIN-2-IL]AMINO}FENIL)-S-METILSULFOXIMIDA, (RS)-S-CICLOPROPIL-S-(4-{[4-{[(1R,2R)-2-HIDROXI-1-METILPROPIL]AMINO}-5-(TRIFLUOROMETIL)PIRIMIDIN-2-IL]AMINO}FENIL)SULFOXIMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE CDK (QUINASAS DEPENDIENTE DE CICLINA) Y DEL CRECIMIENTO DE TUMORES POR LO QUE SON UTILES EN EL TRATAMIENTO DEL CANCER, ENFERMEDADES VIRALES, ENFERMEDADES CARDIOVASCULARES, ENTRE OTROS
PE2011000917A 2008-10-21 2009-10-09 Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk) y produccion de los mismos PE20110546A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08167113A EP2179991A1 (de) 2008-10-21 2008-10-21 Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
PE20110546A1 true PE20110546A1 (es) 2011-08-12

Family

ID=40282208

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000917A PE20110546A1 (es) 2008-10-21 2009-10-09 Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk) y produccion de los mismos

Country Status (38)

Country Link
US (1) US8735412B2 (es)
EP (2) EP2179991A1 (es)
JP (1) JP5564054B2 (es)
KR (1) KR20110069115A (es)
CN (1) CN102197029B (es)
AR (1) AR074053A1 (es)
AU (1) AU2009306733C1 (es)
BR (1) BRPI0920112A2 (es)
CA (1) CA2739739C (es)
CO (1) CO6361926A2 (es)
CR (1) CR20110210A (es)
CU (1) CU24052B1 (es)
CY (1) CY1115590T1 (es)
DK (1) DK2350026T3 (es)
DO (1) DOP2011000107A (es)
EA (1) EA019230B1 (es)
EC (1) ECSP11010992A (es)
ES (1) ES2499028T3 (es)
HN (1) HN2011001019A (es)
HR (1) HRP20140830T1 (es)
IL (1) IL211713A (es)
MA (1) MA32723B1 (es)
MX (1) MX2011004238A (es)
MY (1) MY155230A (es)
NZ (1) NZ592314A (es)
PA (1) PA8846201A1 (es)
PE (1) PE20110546A1 (es)
PL (1) PL2350026T3 (es)
PT (1) PT2350026E (es)
RS (1) RS53523B1 (es)
SA (1) SA109300632B1 (es)
SI (1) SI2350026T1 (es)
TN (1) TN2011000199A1 (es)
TW (2) TWI458716B (es)
UA (1) UA103500C2 (es)
UY (1) UY32190A (es)
WO (1) WO2010046035A1 (es)
ZA (1) ZA201103727B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
DE102010014427A1 (de) 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010014426A1 (de) 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010046720A1 (de) * 2010-09-23 2012-03-29 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung
TW201636330A (zh) * 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
DE102011080991A1 (de) 2011-08-16 2013-02-21 Bayer Pharma AG Verwendung von CCNE2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
DE102011080992A1 (de) * 2011-08-16 2013-02-21 Bayer Pharma AG Verwendung von MAD2L2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
US9133171B2 (en) 2011-09-16 2015-09-15 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
MX2014011240A (es) * 2012-03-21 2014-10-15 Bayer Ip Gmbh Uso de (rs)-s-ciclopropil-s-(4-{[4-{[(1r, 2r)-2-hidroxi-1-metilpro pil]oxi}-5-(trifluorometil)pirimidin-2-il]amino}fenil)sulfoximida para el tratamiento de tumores especificos.
WO2016059086A1 (en) * 2014-10-16 2016-04-21 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
JP2022500388A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
EP1017394B1 (en) 1997-07-12 2005-12-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US6632820B1 (en) 1998-08-29 2003-10-14 Astrazeneca Ab Pyrimidine compounds
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
AU2002312933B2 (en) 2001-05-29 2007-12-06 Schering Ag CDK inhibiting pyrimidines, production thereof and their use as medicaments
AU2003212282A1 (en) * 2002-03-11 2003-09-22 Schering Aktiengesellschaft Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament
US7504410B2 (en) 2002-11-28 2009-03-17 Schering Aktiengesellschaft Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
JP2008514571A (ja) * 2004-09-29 2008-05-08 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 細胞周期−キナーゼまたはレセプター−チロシン−キナーゼインヒビターとしての置換２−置換アニリノピリミジン類、それらの製造および薬剤としての使用
DE102005062742A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
DE102006027156A1 (de) * 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
EP2179992A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
US20110294838A1 (en) 2011-12-01
CY1115590T1 (el) 2017-01-04
RS53523B1 (en) 2015-02-27
TW201444803A (zh) 2014-12-01
CN102197029A (zh) 2011-09-21
SA109300632B1 (ar) 2013-07-04
EA019230B1 (ru) 2014-02-28
JP5564054B2 (ja) 2014-07-30
HRP20140830T1 (hr) 2014-11-21
EA201100623A1 (ru) 2011-12-30
MA32723B1 (fr) 2011-10-02
IL211713A0 (en) 2011-06-30
JP2012506391A (ja) 2012-03-15
KR20110069115A (ko) 2011-06-22
TWI458716B (zh) 2014-11-01
PL2350026T3 (pl) 2014-11-28
EP2350026A1 (de) 2011-08-03
CU24052B1 (es) 2014-12-26
BRPI0920112A2 (pt) 2015-12-22
TW201020237A (en) 2010-06-01
PT2350026E (pt) 2014-09-12
CU20110088A7 (es) 2011-12-28
CA2739739C (en) 2016-12-20
WO2010046035A1 (de) 2010-04-29
AU2009306733B2 (en) 2015-11-12
DK2350026T3 (da) 2014-09-15
UY32190A (es) 2010-05-31
NZ592314A (en) 2013-02-22
ZA201103727B (en) 2014-11-26
HN2011001019A (es) 2013-07-01
MX2011004238A (es) 2011-05-23
CA2739739A1 (en) 2010-04-29
AR074053A1 (es) 2010-12-22
AU2009306733A1 (en) 2010-04-29
US8735412B2 (en) 2014-05-27
CN102197029B (zh) 2014-05-14
EP2350026B1 (de) 2014-06-18
ES2499028T3 (es) 2014-09-26
ECSP11010992A (es) 2011-05-31
TN2011000199A1 (en) 2012-12-17
TWI496774B (zh) 2015-08-21
AU2009306733C1 (en) 2016-07-14
CO6361926A2 (es) 2012-01-20
EP2179991A1 (de) 2010-04-28
UA103500C2 (uk) 2013-10-25
IL211713A (en) 2015-04-30
CR20110210A (es) 2011-06-08
PA8846201A1 (es) 2010-05-26
MY155230A (en) 2015-09-30
SI2350026T1 (sl) 2014-10-30
DOP2011000107A (es) 2011-05-15

Similar Documents

Publication Publication Date Title
PE20110546A1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk) y produccion de los mismos
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
TR201815062T4 (tr) Viral enfeksiyonların tedavisine yönelik pirimidin deriveleri.
EA201100944A1 (ru) Производные изоксазола, предназначенные для применения в качестве регуляторов роста растений
EA201490696A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантной idh
PE20201448A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
BRPI0814065B8 (pt) derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
UY30897A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
EA201070988A1 (ru) Противовирусные терапевтические средства
PE20061198A1 (es) Derivados de pirazol como inhibidores de cdk y gsk
PE20130651A1 (es) Derivados de imidazopiridina y su procedimiento de preparacion
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20131165A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
AR065015A1 (es) Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
UA117800C2 (uk) Похідні урацилу або тиміну для лікування гепатиту с
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
AR066972A1 (es) Derivados azapeptidicos
PE20140966A1 (es) Quinazolincarboxamida azetidinas

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed